** Shares of healthcare tech firm Veeva Systems VEEV.N rise ~1.4% to $276.7 premarket
** J.P. Morgan upgrades stock rating to "overweight" from "neutral"; raises PT to $330 from $290
** Brokerage says it is optimistic about new opportunities created by Veeva's partnership with IQVIA IQV.N (formerly IMS Health and Quintiles) and its use of Agentic Artificial Intelligence $(AI)$
** Last month, IQVIA and Veeva announced long-term partnerships covering both clinical and commercial areas, along with resolution of all outstanding disputes
** Veeva competes with Salesforce CRM.N and other software providers, but no one matches its product depth, especially across Vault CRM Suites, brokerage says
** Stock rated "buy" on average; median PT is $322 - data compiled by LSEG
** As of last close, VEEV has risen ~30% this year
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com))